Editor’s Note: Cannabis is still a new industry, filled with profit potential that isn’t always easy to see unless you have the time to keep up with every single development. That’s why the National Institute for Cannabis Investors shares its findings – so you don’t have to dig through search engines and dense research to find the opportunity. And this just-released update from them gives you two companies leading the way in a process that’s yielding more reliable, safe cannabis products.
Cannabidiol (CBD) has been the poster child of the cannabis-based medicine movement for years. CBD is the cannabis plant’s primary non-psychoactive compound.
In a highly concentrated form, it makes an incredibly effective pharmaceutical – one that could even prove to be a powerful weapon in the fight against COVID-19.
And it’s emerging as a lucrative market in its own right – one that’s making folks like you a lot of money already.
Each of these compounds, and all their possible combinations, represents a veritable ocean of new possibilities for medical researchers.
For you, that means an endless pool of new profit opportunities just waiting to be unlocked…
A New Way to Make Reliable and Safe Cannabis Products
The process that’s key to unlocking those profits is biosynthesis. At its core, biosynthesis is a naturally occurring process that uses simple chemical compounds to create more complex compounds. This, of course, is an oversimplification of an unbelievably sophisticated process.
Cannabis companies can use biosynthesis to turn microbes such as yeast into tiny cannabinoid factories.
Once the genome of, say, brewer’s yeast has been altered to manufacture a cannabinoid like the rare cannabigerol (CBG) instead of alcohol, these trace cannabinoids can be manufactured very cheaply in vast quantities.
By using biosynthesis to manufacture cannabinoids, you also get a much more consistent, reliable, and safe end product – something that is important for all cannabis consumers, but particularly when it comes to pharmaceutical-grade products.
Looking to the future, that type of safety and consistency could make biosynthesis an appealing option for receiving U.S. Food and Drug Administration (FDA) approval, as the FDA has expressed concern over those factors when it comes to cannabis-based products.
Today, there are cannabis companies out there already taking advantage of biosynthesis, and even more that could benefit from it down the road.
Using Biosynthesis to Unlock Profits
InMed Pharmaceuticals Inc. (OTC: IMLFF), for example, is leading the way in testing the therapeutic properties of the rare cannabinoid, cannabinol (CBN). And it’s using biosynthesis to do so.
The company just entered its second Phase 1 clinical trial for its INM-755 product, which is being studied for the treatment of the rare genetic skin disease, epidermolysis bullosa.
Then there’s GW Pharmaceuticals Inc. (NASDAQ: GWPH) – a first mover in the pharmaceutical CBD market with its blockbuster CBD drug, Epidiolex.
Today, it’s testing the efficacy of yet another rare cannabinoid, cannabidivarin (CBDV), in treating epilepsy and autism spectrum disorders. Much like it did with CBD, if its clinical trials are successful, GW Pharma could position itself as a first mover in the pharmaceutical CBDV market.
That could potentially be hugely profitable for the company if it’s able to see even half the success that it has with Epidiolex. Epidiolex sales are on track to reach $500 million in 2020, and National Institute for Cannabis Investors Executive Director Don Yocham expects that number could surpass $1 billion next year.
Because CBDV is found in much smaller quantities in the cannabis plant, biosynthesis could prove to be essential to GW Pharma accomplishing its goals.
In Don’s view, 10 years down the road, most cannabinoids will be sourced through biosynthesis – including THC and CBD.
InMed and GW Pharma are just two examples, but there are dozens of pharmaceutical companies out there working to harness the healing properties of the cannabis plant.
And the best way to keep track of the movers and shakers is through our proprietary NICILytics database.
It holds the most up-to-date data and research on over 300 cannabis companies from every subsector you could think of – including the lucrative pharmaceutical sector.
With the NICILytics database, you can find ratings and in-depth analyst reports for each and every company so you can easily identify the pot stocks that could give you the best bang for your buck.
About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.To get full access to all Money Morning content, click here.
Disclaimer: © 2020 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201.
Source: Money Morning